Non-Invasive Detection of Pulmonary Right-to-Left Shunts Using the SONAS Ultrasound Device (SONAS)

February 10, 2026 updated by: Prof. Marco C. Post, St. Antonius Hospital

Novel Approach For The Non-Invasive Detection of Pulmonary Right-to-Left Shunts

The goal of this clinical trial is to learn how well the SONAS ultrasound device can detect right-to-left shunts of adults with hereditary hemorrhagic telangiectasia (HHT) who are already scheduled for a contrast bubble echocardiogram (TTCE). The main questions it aims to answer are:

  1. How accurately does SONAS detect right-to-left shunts compared to the standard TTCE test?
  2. Can SONAS results help tell the difference between shunts in the heart and shunts in the lungs?

Participants will wear a headband with the SONAS device on the head while they undergo their routine TTCE bubble test. They will receive the usual contrast (agitated saline) through a vein, and both SONAS and TTCE signals will be recorded at the same time. There will be one examination in rest, and one during a breathing exercise (the Valsalva manoeuvre).

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

This study is being done to find out whether a new ultrasound device called SONAS can safely and reliably detect "right-to-left shunts" in people with hereditary hemorrhagic telangiectasia (HHT). Right-to-left shunts are abnormal connections between blood vessels that allow blood to bypass the lungs and go directly from the right side of the heart to the left side. This can increase the risk of problems such as stroke or brain abscess. Today, these shunts are usually found with a "bubble heart ultrasound" (TTCE), which needs experienced staff and can be time-consuming. SONAS is a small, portable device that detects blood flow signals in the brain after a bubble injection and may offer a simpler way to detect these shunts.

In this study, all participants are are already scheduled to have a bubble heart ultrasound as part of their regular care. The study adds the SONAS device on top of this routine test. During the procedure, a soft headband with small ultrasound sensors is placed in frond of the ears on both sides of the head. At the same time, the standard bubble test is done: normal saline mixed with a small amount of the participant's blood and some air is injected into a vein, and the heart is imaged with ultrasound. Participants will be asked to perform a straining manoeuvre (called a Valsalva) to see if this makes a shunt more visible. While this is happening, SONAS continuously records signals from the brain that show when the bubbles pass through.

There will be a comparison between what SONAS shows with what the standard heart ultrasound shows. By comparing these results, the researchers want to see how closely the SONAS score matches the standard test and whether certain SONAS outcomes indicate a clinically important shunt. They will also look at the timing and pattern of the bubble signals to explore whether SONAS can help tell the difference between shunts that come from the heart and those that come from the lungs. The study does not change any decisions about diagnosis or treatment: all medical decisions remain based on the usual heart ultrasound and other standard tests.

Throughout the procedure, the safety and comfort of participants are closely monitored. SONAS does not deliver any contrast or radiation. All problems or unusual events that occur during or shortly after the combined test are recorded. The information collected in this study will help determine whether SONAS is a practical, safe, and useful tool to support or simplify screening for right-to-left shunts.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
40

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age 18 years or older.
  • Suspected or confirmed hereditary hemorrhagic telangiectasia (HHT).
  • Incidentally: Patients who have experienced cryptogenic stroke

Exclusion Criteria:

  • Pregnancy or breastfeeding.
  • Known or suspected fracture(s) of the temporal / parietal skull bones, or with open skin injuries in the anatomical area of the temporal / parietal lobes.
  • Patients with known metal skull implants in the anatomical area of the temporal / parietal bones, or with anatomical formation of the head or ear tha may interfere with proper headset placement.
  • Patients with known allergies or reactions to parabens, which are present in the gel pad material of the applied part.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: SONAS Ultrasound During Contrast Echocardiography
This study has a single arm in which all participants undergo SONAS monitoring during a standard contrast echocardiogram (transthoracic contrast echocardiography). In this arm, adults with (possible) hereditary hemorrhagic telangiectasia or PFO who are already scheduled for a clinically indicated bubble echocardiogram have a headband with the SONAS ultrasound device examination. Agitated saline is injected into a vein as part of usual care, and the heart is imaged with echocardiography while SONAS simultaneously records ultrasound signals from the brain.
Device: Transcranial Ultrasound Device
The intervention is the SONAS ultrasound device used during a routine bubble echocardiogram. A battery-powered unit connects to a headset with two ultrasound sensors placed in front of the ears. The device does not deliver contrast or drugs; it records ultrasound signals in the brain while standard agitated saline is injected and the heart is imaged. SONAS analyzes bubble-related signals and calculates a numeric score to evaluate right-to-left shunts without changing the usual echocardiography protocol.
Other Names:
  • SONAS
  • Foqus

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Capability of detecting Right-to-Left Shunts
Time Frame: Periprocedurally
Device capability of detecting High Intensity Transient Signals (HITS) using SONAS in presence of RLS, as confirmed by reference method TTCE. SONAS output is expressed as maximum HITS Density Score (0-100%). TTCE outcome is assessed by RLS grade (0-3), maximum microbubble count in left ventricle, and corrected change in echo density.
Periprocedurally
Diagnostic accuracy
Time Frame: Periprocedurally
Diagnostic accuracy (sensitivity and specificity) of SONAS for detection of clinically significant RLS (≥grade 2 on TTCE) at different HITS Density Score thresholds.
Periprocedurally

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Distinguishing intracardiac from pulmonary Right-to-Left Shunts
Time Frame: Periprocedurally
SONAS capability to distinguish intracardiac from pulmonary RLS based on time delay between contrast administration and first HITS occurrence, and difference in HITS Density Score between rest and Valsalva maneuver.
Periprocedurally
Test-retest reliability of SONAS for HITS assessment
Time Frame: Periprocedurally
Test-retest reliability of SONAS for HITS assessment using Intraclass Correlation Coefficient.
Periprocedurally

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
St. Antonius Hospital

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Burl Concepts, Inc.

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Martijn C. Post, Professor, St. Antonius Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 7, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
April 1, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
April 1, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
February 3, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 10, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
February 17, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
February 17, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 10, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
February 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • R25.111

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

All anonymized Individual Patient Data that underlie results in the publication.

IPD Sharing Time Frame

Beginning 3 months and ending 2 years after the publication of results.

IPD Sharing Access Criteria

Fellow researchers interested in doing a meta-analysis of data will be able to access the IPD and supporting information. There will be access to the Study Protocol and anonymized individual patient data. Access is possible by contacting the Central Contact Person or Principal Investigator of the study.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on PFO - Patent Foramen Ovale

Clinical Trials on Transcranial Ultrasound Device

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings